Sparking an insight on eyesight
By Jan Jarvis
A decade ago, a Fort Worth startup began developing an eye drop that may literally change the way 100 million Americans who suffer from the blurry near vision of presbyopia see the world.
The huge insight on eyesight that Encore Vision President and CEO Bill Burns had 10 years ago is moving closer to becoming a reality with the recent announcement that Swiss pharmaceutical giant Novartis is acquiring the startup for an undisclosed amount.
Burns, whose company was helped by the TECH Fort Worth-UNT Health Science Center Acceleration Lab, said the Novartis acquisition “represents an important step in continuing the development of EV06 Ophthalmic Solution, a first-in-class treatment for the millions with quality-of-life limiting presbyopia.”
The drops are expected to provide relief from presbyopia, a common condition that typically occurs in middle to old age.
“There are no approved medical treatments for presbyopia,” Burns said. “There hasn’t been a great advancement since Ben Franklin invented bifocals. So it’s time.”
The drops work by reducing stiffness in the eye lens that occurs with aging. By restoring flexibility, the drops allow the lens to thicken in the center, making it easier to focus on nearby objects. Those who use the drops daily should be able to eliminate or reduce their use of glasses.
Virtually everyone over 45 experiences the condition, which makes it difficult to focus on objects, read and see small print. Until now the only treatment for the condition has been glasses and sometimes surgery.
Burns said the assistance he received from the TECH Fort Worth-UNTHSC Acceleration Lab in the early stages of development was a major asset.
“UNT Health Science Center played an instrumental role in Encore Vision research and development activities over the years,” Burns said. “Through the relationship between TECH Fort Worth and UNTHSC, Encore Vision was given access to laboratory space, faculty, the health science library and the opportunity to interact with experienced industry executives through the Executives in Residence program.”
Novartis said in a statement that the acquisition will add a first-in-class disease modifying topical treatment for presbyopia to its ophthalmology pipeline. Terms were not disclosed.
Encore Vision, which has been a UNTHSC Acceleration Lab client company for many years, is another success story for UNTHSC and its partnership with TECH Fort Worth, said Lawrence E. (Joe) Allred, PhD, Associate Vice President for Research & Innovation
Last year ZS Pharma was purchased by AstraZeneca for $2.7 million. ZS Pharma received help through the Accelerator Lab in the development of a deadly blood condition known as hyperkalemia.
By Jan Jarvis HSC Insider Learn more about UNTHSC’s people and programs by signing up for the weekly HSC Insider email. Time is critical when someone has a stroke – especially the first three to four hours. That’s how long someone has to get to the hospi...Read more
Nov 19, 2018
By Alex Branch The physician assistant students huddled around Davey, a 5-year-old boy who wheezed and struggled to breathe. Students studied his medical history chart and leaned down to talk to him on the exam table. They calmed Davey’s mother and watched his vital signs on a digi...Read more
Nov 14, 2018
By Alex Branch After more than 11 years of serving charbroiled steak burgers to a hungry Health Science Center, Mac Thompson is hanging up his red apron. Thompson will retire from Fun on the Bun this month. Beloved for his warm, gentle humor, Thompson is a fixture on the first flo...Read more
Nov 13, 2018
By Jan Jarvis One of the ways researchers are exploring treating the optic nerve damage of glaucoma is an injection directly into the eye. But Suchismita Acharya, PhD, is studying a different approach that not only takes the pain out of treating this blinding disease but also holds t...Read more
Nov 12, 2018